Drug Trial Radar · NCT02097485
Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation
Last checked: Nov 20, 2026Latest source record: May 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
May 2014
Primary completion
Sep 2014
Study completion Oct 2014
Sponsor
- Lead sponsor
- Dr. Reddy's Laboratories Limited, IndiaIndustry
- Sponsor type
- Industry
- First posted
- Mar 27, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study was to evaluate ovicidal efficacy of a single application of abametapir lotion 0.74% w/w intended for the treatment of head lice.
Conditions
- Head Lice Infestation
Interventions
Abametapir Lotion 0.74% w/wDrug
200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
Vehicle LotionDrug
control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Hatched Eggs Pre Treatment Relative to Post TreatmentTime frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Head Lice Treatment Centre
Ringwood East, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.